Aarti Drugs soars with Q4 FY25 profit spike—But what’s behind the full-year revenue drop?

Aarti Drugs Limited delivered a strong recovery in its fourth-quarter earnings for FY25, supported by a rebound in API exports and easing input costs, even as the full fiscal year recorded a decline in revenue and EBITDA. The Mumbai-based pharmaceutical manufacturer reported a 33% year-on-year increase in Q4 net profit and a 9% jump in revenue, defying the broader market challenges in global API pricing and regulatory pressures. However, annual revenues slipped by 5% due to a tough first half, marked by raw material cost volatility and muted demand in the formulations segment.

How Did Aarti Drugs Perform in Q4 FY25?

For the quarter ending March 31, 2025, Aarti Drugs posted consolidated revenue of ₹678.6 crore, up 9% year-on-year. The company benefited from a 15.5% volume growth in APIs, driven mainly by export demand. Domestic revenue increased 2% while exports surged 28%, contributing to 40% of standalone revenue.

Operating profit (EBITDA) rose 10% year-on-year to ₹95.2 crore with margins holding steady at 14%, up 280 basis points sequentially. Net profit reached ₹62.8 crore, a 33% increase from the previous year, raising the PAT margin to 9.2% from 7.6%.

Segmentally, the API business generated ₹553.1 crore in Q4 revenue, rising 10% YoY, while Specialty Chemicals grew 18% to ₹39 crore. Formulations fell 4% to ₹64.8 crore, with 62% of this revenue attributed to exports.

What Do FY25 Results Indicate for Aarti Drugs?

Despite the strong quarterly performance, FY25 closed on a subdued note. Annual consolidated revenue declined 5% to ₹2,403.4 crore, while EBITDA dropped by a similar percentage to ₹303.4 crore. Net profit marginally decreased to ₹168.1 crore from ₹171.6 crore in FY24, though PAT margin slightly improved to 7.0%.

The company attributed this weakness to falling input prices and high volatility in global API markets, exacerbated by the ongoing pharmaceutical trade tensions between the U.S. and China. These dynamics disrupted raw material supply chains, altered cost structures, and created pricing uncertainties—especially for key molecules such as Ciprofloxacin Hydrochloride and Metformin HCL.

What Drove Segment-Level Performance?

Aarti Drugs’ API segment contributed the bulk of FY25 revenue at ₹1,938.4 crore, marking a 4% decline from the previous year. Within this, the therapeutic breakdown included antibiotics (39%), anti-diabetics (15%), anti-protozoals (20%), anti-inflammatories (12%), antifungals (9%), and others (5%).

The formulations segment declined sharply by 23% to ₹248.9 crore, reflecting persistent margin pressure and softer export demand. Specialty Chemicals brought in ₹130 crore, growing marginally by 3%, while intermediates and others jumped 17% to ₹69.4 crore.

What Are Aarti Drugs’ Strategic Moves?

In FY25, the company invested ₹177 crore in capital expenditure, focusing on capacity expansion, backward integration, and new product launches. Most of this was funded through internal accruals and some term loans, maintaining a conservative debt-to-equity ratio of 0.45. A dividend payout of ₹69 crore was also completed during the year.

Notably, the Sayakha greenfield project in Gujarat—aimed at backward integration of anti-diabetic product intermediates—commenced trial production and is expected to stabilize within the current quarter. Meanwhile, the Tarapur facility, initially beset by operational delays, is scaling toward 700 tonnes per month by June 2025, with a longer-term goal of reaching 1,600 tonnes by FY26.

Additionally, the company entered a Share Subscription and Shareholders’ Agreement with Pro-Zeal Green Power Nine Pvt Ltd to acquire a 26.25% stake in a 24.4 MWp solar power project. This move aligns with its ESG roadmap and aims to reduce its energy cost base.

How Will the USFDA Update Impact Aarti Drugs?

A pivotal development in FY25 was the lifting of the USFDA Import Alert 66-40 on Aarti Drugs’ API manufacturing facility at Tarapur, Maharashtra. With the alert withdrawn in February 2025, the company resumed U.S. exports of APIs like Ciprofloxacin HCl, Zolpidem Tartrate, Raloxifene HCl, Celecoxib, and Niacin.

This clearance restores Aarti Drugs’ regulatory credibility and is expected to unlock higher-margin growth in regulated markets, particularly in North America, where FDA compliance significantly enhances business potential and investor confidence.

What Does the Market Say? Sentiment and Valuation Trends

As of May 7, 2025, Aarti Drugs’ shares surged by 20% to close at ₹419.85 on the NSE, reacting positively to the Q4 FY25 results. This rally comes despite the stock declining 15.05% over the past six months and 14.52% in the last year, suggesting that investors see renewed growth visibility ahead.

Valuation-wise, the stock trades at a P/E ratio of 22.95, slightly below the industry average of 26.96, indicating moderate valuation comfort. The P/B ratio stands at 2.49, and the company has maintained an average ROE of 13.8% over the last three years, indicating efficient capital allocation.

The 52-week range stands between ₹312.00 and ₹635.00, underscoring past volatility, while the current price rebound places the stock closer to the mid-range of its yearly performance band.

How Are Institutional Investors Positioned?

Promoter holding as of March 2025 was 55.48%, showing a marginal increase from the previous quarter, signaling management confidence. Domestic Institutional Investors (DIIs) increased their stake to 9.70% from 8.77%, reflecting rising domestic confidence. Conversely, Foreign Institutional Investors (FIIs) marginally reduced their holdings from 2.28% to 2.25%.

This trend suggests that local institutions are seeing value in the stock at current levels, especially after the regulatory and export recovery updates. The relatively low FII holding continues to reflect cautious global sentiment amid sector-wide volatility and global API competition.

Analyst Sentiment: What Should Investors Do?

Analyst consensus on Aarti Drugs leans toward a ‘Buy’ recommendation, with an average target price of ₹465, representing an upside potential of over 10% from current levels. The outlook is supported by improving profitability, normalization of raw material costs, green energy investments, and the lifting of USFDA restrictions.

Buy: Investors with a long-term perspective may consider entering or adding to their positions, given the expected pickup in exports and margin tailwinds from cost-efficient operations.

Hold: Existing shareholders may continue to hold as the company’s greenfield expansions and regulatory clearances begin translating into stronger financials.

Sell: Short-term traders or risk-averse investors may choose to exit partially, given the historical volatility and ongoing pricing competition in the formulations space.

What Lies Ahead for Aarti Drugs?

Aarti Drugs appears poised for a more stable FY26, anchored by the ramp-up of backward-integrated capacities, an expanding green energy footprint, and export potential unlocked by USFDA compliance. However, raw material price volatility, formulation pricing pressure, and competitive dynamics—especially from Chinese suppliers—will continue to test the company’s ability to sustain growth and profitability.

The key to future performance will lie in execution of the Gujarat and Tarapur capacity scale-ups, success in capturing regulated markets, and maintaining lean operational structures amid global API fluctuations.